Treatment for recurrent prostate cancer with metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of combining short-term androgen deprivation therapy (ADT) with metastasis-directed therapy (MDT) in patients with oligorecurrent hormone-sensitive prostate cancer. Participants will receive stereotactic body radiation therapy (SBRT) or surgery to target metastases, alongside ADT and androgen receptor targeted therapy. The goal is to determine if this combination can significantly prolong the time patients remain free from metastatic progression and castration-resistant prostate cancer. The study aims to improve patient outcomes by delaying the need for palliative androgen deprivation therapy and its associated side effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically proven initial diagnosis of prostate adenocarcinoma
* Priory treated and controlled primary tumor
* Biochemical recurrence defined by prostate-specific antigen (PSA) values \>0,2 ng/ml (i.e., two consecutive increases) following radical prostatectomy + postoperative radiotherapy and a PSA value of 2 ng/ml above the nadir after high-dose RT.
* Oligorecurrent disease defined as a maximum of 5 extracranial metastases in any organ, diagnosed on PSMA PET-CT or PSMA PET-MRI reported according to the E-PSMA consensus guidelines for interpretation of PSMA-PET (26). Nodal (N1) disease can be included only when accompanied by M1a-c disease, provided that the total number of spots does not exceed 5.
* Serum testosterone level within normal range.
* WHO performance 0-2
* Age \>= 18 years old
* Absence of psychological, sociological or geographical condition potentially hampering compliance with study protocol.
* Patients must be presented at the multidisciplinary board meeting and the inclusion in the trial needs approval by this board.
* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
* 2\. Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.

Exclusion Criteria:

* Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol
* Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial
* Participation in an interventional Trial with an investigational medicinal product (IMP) or device
* Serum testosterone level at castration level.
* PSA rise while on active treatment (LHRH-agonist, LHRH antagonist, anti-androgen, maximal androgen blockade, oestrogen)
* Presence of poly-metastatic disease, defined as more than 5 metastatic lesions.
* Active malignancy other than prostate cancer that could potentially interfere with the interpretation of this trial.
* Previous treatments (RT, surgery) or comorbidities rendering new treatment with SBRT impossible.
* Contra indications for intake of enzalutamide (seizure or any condition that may predispose to seizure; significant cardiovascular disease within the last three months including myocardial infarction, unstable angina, congestive heart failure, ongoing arrythmias of grade \> 2 or a thromboembolic event).
* Not able to understand the treatment protocol or sign informed consent.

Where it's running

• University Hospitals Leuven
  Leuven, Belgium Recruiting

Study contacts

• Study coordinator: Kato Rans, MD
• Email: kato.rans@uzleuven.be
• Phone: 003216340110

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How social, structural, and lifestyle factors relate to prostate cancer outcomes in diverse men

  This study looks at whether social and lifestyle factors help explain differences in prostate cancer outcomes among Black, Hispanic, and Asian men who have had a radical prostatectomy.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07690579

• Epidemiology, diagnosis, and treatment patterns of prostate cancer in Algeria

  This project collects medical and treatment information to see how prostate cancer is diagnosed and managed in Algerian men with confirmed disease.

  Recruiting at 21 sites Société Algérienne de Formation et Recherche en Oncologie · Adrar, Algeria and 23 other locations · NCT07484971

• Immediate simulation-free SBRT for people with up to five metastatic tumors

  This tests whether giving stereotactic body radiation therapy (SBRT) right away without a separate CT simulation helps people with up to five metastatic cancer spots get treatment faster.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT07079098

• Mevrometostat plus enzalutamide versus enzalutamide alone for men with metastatic castration‑sensitive prostate cancer who are ARPI‑naïve

  This trial will test whether adding the investigational drug mevrometostat to enzalutamide helps men with metastatic castration‑sensitive prostate cancer who have not received androgen receptor pathway inhibitors or chemotherapy.

  Recruiting at 145 sites Phase 3 Pfizer · Huntsville, Alabama and 318 other locations · NCT07028853

• Mini-tumors to guide treatment for aggressive prostate cancer

  We will grow tiny, patient-derived mini-tumors in the lab to test which treatments work best for men with aggressive or metastatic prostate cancer.

  Recruiting Maastricht Radiation Oncology · Heerlen, Limburg and 2 other locations · NCT07004582

• Treatment for advanced prostate cancer using Pluvicto

  This study is testing if a new treatment called Pluvicto can help men with advanced prostate cancer that has spread to their bones feel better and improve their quality of life.

  Recruiting Phase 2 Excel Diagnostics and Nuclear Oncology Center · Houston, Texas · NCT06972628

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.